Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme, Industry Analysts Relieved By Particulars In Draft Consent Decree

This article was originally published in The Pink Sheet Daily

Executive Summary

Unveiling its first-quarter financial results, Genzyme reports significant year-over-year sales decreases for Cerezyme and Fabrazyme.

You may also be interested in...



Genzyme Warns Of Further Shortages Of Cerezyme, Fabrazyme

Fabrazyme may be unavailable in some regions from July through September, the company warned.

Genzyme Warns Of Further Shortages Of Cerezyme, Fabrazyme

Fabrazyme may be unavailable in some regions from July through September, the company warned.

With Proxy Fight Averted, Genzyme Can Review Damage Done By A Year Of Manufacturing Troubles

Now that Genzyme has avoided a proxy fight with Carl Icahn and associates, the biotech's next step likely will be to consider the damage left by a year's worth of manufacturing woes and the problems that resulted, including shortages of its top-selling products, the launch of new competition to those drugs, and an FDA consent decree governing operations at its Allston Landing, Mass., plant

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel